Pericarditis resident survival guide: Difference between revisions
No edit summary |
No edit summary |
||
Line 306: | Line 306: | ||
❑ Avoid steroids to treat an initial episode of pericarditis <br> | ❑ Avoid steroids to treat an initial episode of pericarditis <br> | ||
---- | ---- | ||
'''Order tests to identify specific | '''Order tests to identify the specific etiology'''<br> | ||
---- | ---- | ||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br> | ❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br> | ||
Line 360: | Line 360: | ||
❑ Avoid steroids to treat an initial episode of pericarditis <br> | ❑ Avoid steroids to treat an initial episode of pericarditis <br> | ||
---- | ---- | ||
'''Order tests to identify specific | '''Order tests to identify the specific etiology'''<br> | ||
---- | ---- | ||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br> | ❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br> | ||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Treat according to the etiology]] | ❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Treat according to the etiology]] | ||
</div>| I01=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''[[ | </div>| I01=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''Intitate [[aspirin]] therapy'''<br> | ||
---- | ---- | ||
'''[[aspirin|High-dose aspirin]]''' <br> | |||
:❑ Orally 800 mg QID or TDS x 7-10 days <BR> | :❑ Orally 800 mg QID or TDS x 7-10 days <BR> | ||
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br> | :❑ Gradual tapering by 800 mg/week for 3 additional weeks <br> | ||
Line 373: | Line 373: | ||
:❑ [[Omeprazole]] (20 mg/day) <br> | :❑ [[Omeprazole]] (20 mg/day) <br> | ||
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]] <br> | ❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]] <br> | ||
'''[[Steroids]]'''<br> | |||
❑ Avoid steroids to treat an initial episode of pericarditis <br> | |||
---- | ---- | ||
''' | '''Life style modification'''<br> | ||
---- | ---- | ||
❑ | ❑ In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br> | ||
</div>| I04=<div style="float: left; text-align: left; width: 20em; padding:1em;">''' | ❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings<br> | ||
</div>| I04=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate medical therapy'''<br> | |||
---- | ---- | ||
'''NSAID's'''<br> | |||
❑ [[Ibuprofen]]: <br> | ❑ [[Ibuprofen]]: <br> | ||
:❑ Preferred<br> | :❑ Preferred<br> | ||
Line 391: | Line 396: | ||
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | :❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | ||
:❑ [[Omeprazole]] (20 mg/day) <br> | :❑ [[Omeprazole]] (20 mg/day) <br> | ||
'''[[Colchicine]]'''<br> | '''[[Colchicine]]'''<br> | ||
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334 }} </ref> <br> | ❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334 }} </ref> <br> | ||
❑ Can be used alone<BR> | ❑ Can be used alone<BR> | ||
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR> | ❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR> | ||
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR> | ❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR> | ||
'''[[Steroids]]'''<br> | |||
❑ Avoid steroids to treat an initial episode of pericarditis <br> | |||
---- | ---- | ||
''' | '''Life style modification'''<br> | ||
---- | ---- | ||
❑ | ❑ In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br> | ||
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings<br> | |||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | | | |`|-|v|-|'| | | }} | {{familytree | | | | | | | | | | | | |`|-|v|-|'| | | }} | ||
Line 416: | Line 426: | ||
❑ Indication that the underlying cause may not be viral or idiopathic in nature. <br> | ❑ Indication that the underlying cause may not be viral or idiopathic in nature. <br> | ||
❑ Inpatient therapy <BR> | ❑ Inpatient therapy <BR> | ||
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order sepcific tests to identify | ❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order sepcific tests to identify the etiology and treat accordingly]] <br> | ||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | | | | | | | | | | |}} | ||
Line 422: | Line 432: | ||
===Treatment of Recurrent Pericarditis=== | ===Treatment of Recurrent Pericarditis=== | ||
Shown below is an algorithm summarizing the management of recurrent [[pericarditis]] in adults.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056 }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693 }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref> | Shown below is an algorithm summarizing the management of recurrent [[pericarditis]] in adults which encompass the '''incessant type''' (relapses on discontinuation of anti-inflammatory) and the '''intermittent type''' (widely varying symptom free interval without medical therapy).<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056 }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693 }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref> | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{familytree | | | | | | | | | | A01 | | | | | | | | | | A01=Recurrent pericarditis}} | {{familytree | | | | | | | | | | A01 | | | | | | | | | | A01=Recurrent [[pericarditis]]}} | ||
{{familytree | | | | | | | | | | {{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the clinical, EKG and imaging findings'''<br> | {{familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the clinical, EKG and imaging findings'''<br> | ||
❑ Characteristic [[Pericarditis history and symptoms|acute pericarditis symptoms]] <br> | ❑ Characteristic [[Pericarditis history and symptoms|acute pericarditis symptoms]] <br> | ||
Line 441: | Line 444: | ||
❑ Other clinical suspicion: <br> | ❑ Other clinical suspicion: <br> | ||
:❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease | :❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease | ||
:❑ Early corticosteroid treatment causing augmented viral | :❑ [[Corticosteroid]] treatment during the first episode | ||
:❑ Early [[corticosteroid]] treatment causing augmented viral replication </div>}} | |||
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | {{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">''' | {{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Initiate medical therapy'''<br> | ||
❑ [[ | ---- | ||
:❑ | '''[[NSAIDs]]'''<br> | ||
❑ [[ | ❑ Avoid in [[coronary artery disease]] patients<br> | ||
:❑ | ❑ [[Ibuprofen]]: <br> | ||
:❑ Effective in cases where NSAIDs failed to prevent relapses | :❑ Preferred<br> | ||
❑ | :❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br> | ||
:❑ Gradual tapering every 2-3 days <br> | |||
❑ [[Indomethacin]]: <br> | |||
:❑ Orally 50 mg TDS x 1-2 weeks<br> | |||
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br> | |||
'''[[Aspirin]]'''<br> | |||
❑ Drug of choice in patients with pre-existing [[coronary heart disease]]<br> | |||
❑ [[aspirin|High-dose aspirin]]: <br> | |||
:❑ Orally 800 mg QID or TDS x 7-10 days <BR> | |||
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br> | |||
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]] <br> | |||
'''[[Colchicine]]:'''<br> | |||
❑ Effective in cases where NSAIDs failed to prevent relapses<br> | |||
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334 }} </ref> <br> | |||
❑ Can be used alone<BR> | |||
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR> | |||
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR> | |||
'''Add gastroprotective agents:'''<br> | |||
❑ [[Misoprostol]] (600 to 800 mg/day)<BR> | |||
❑ [[Omeprazole]] (20 mg/day) <br> | |||
---- | |||
'''Life style modification'''<br> | |||
---- | |||
❑ Excercise restriction until symptom resolution<br> | |||
<br> | |||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | {{familytree | | | | | | | | | | |!| | | | | | | | | | |}} | ||
Line 462: | Line 496: | ||
{{familytree | | | | | | | | F01 | | F02 | | | | | | | | F01=<div style="float: left; text-align: left; padding:1em;">'''Taper [[steroids]]'''<br> | {{familytree | | | | | | | | F01 | | F02 | | | | | | | | F01=<div style="float: left; text-align: left; padding:1em;">'''Taper [[steroids]]'''<br> | ||
❑ Taper dose over a three-month period <br> | ❑ Taper dose over a three-month period <br> | ||
❑ If symptoms recur | |||
::❑ Start the last dose that suppressed the symptoms | ::❑ Start the last dose that suppressed the symptoms | ||
::❑ Maintain the dose for 2-3 weeks and then taper | ::❑ Maintain the dose for 2-3 weeks and then taper | ||
❑ Add [[colchicine]] or [[NSAIDs]] at the end of tapering of steroids | |||
</div>| F02=<div style="float: left; text-align: left; padding:1em;"> | </div>| F02=<div style="float: left; text-align: left; padding:1em;"> | ||
❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br> | ❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br> | ||
Line 474: | Line 508: | ||
{{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br> | {{familytree | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br> | ||
❑ Maintain the patient on [[steroid]] free regimen for several weeks before the procedure | ❑ Maintain the patient on [[steroid]] free regimen for several weeks before the procedure | ||
❑'''[[Pericarditis 1 resident survival guide#Management#Etiology Specific Management| | ❑'''[[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order tests to identify the specific etiology and treat accordingly]]</div>}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Line 483: | Line 517: | ||
! Clinical subgroups!! Specific investigations!! Treatment | ! Clinical subgroups!! Specific investigations!! Treatment | ||
|- | |- | ||
| Viral pericarditis|| ❑ | | Viral pericarditis|| ❑ Perform testing for viral etiologies in immunocompromised and [[HIV]] infected patients <br> ❑ Diagnostic [[pericardiocentesis]]<br>:❑ Analysis of [[pericardial fluid]] (transudate or exudate)<br> :❑ [[PCR]] or in-situ hybridisation | ||
|| ❑ [[CMV]] pericarditis: Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16 <br>❑ [[Coxsackie B]] pericarditis: [[Interferon]] alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week<br> ❑ [[Adenovirus]] and [[parvovirus B19]] perimyocarditis: [[Immunoglobulin]] 10 g IV at day 1 and 3 for 6-8 hours | |||
|- | |- | ||
| Purulent pericarditis|| ❑ Diagnostic [[pericardiocentesis]] in cases of high clinical suspicion <br> :❑ [[Gram stain]], acid fast stain, fungal stain, and cultures of the pericardial fluid <br> :❑ Protein, glucose and cell count <br> ❑ Gram stain, acid fast stain, fungal stain, and cultures of other body fluids ||❑ Therapeutic [[pericardiocentesis]] or [[pericardial window]]<br> ❑ [[Pericardiectomy]] may be used in treatment of recurrent pericardial efussion and in patients with dense adhesions, loculated and thick purulent effusion<br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antimicrobial therapy]] <br> :❑ Intiate antistaphylococcal antibiotic plus [[aminoglycoside]], followed by tailored antibiotic therapy according to pericardial fluid and blood cultures<br> :❑ Empiric regimen can be started for the following <br> ::❑ [[Immunosuppression]]<br> ::❑ Concurrent infection at another body site<br> ::❑ Presence of intravascular lines or prosthetic devices <br> ::❑ Recent antimicrobial therapy <br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antifungal therapy]] | | Purulent pericarditis|| ❑ Diagnostic [[pericardiocentesis]] in cases of high clinical suspicion <br> :❑ [[Gram stain]], acid fast stain, fungal stain, and cultures of the pericardial fluid <br> :❑ [[Protein]], [[glucose]] and cell count <br> ❑ [[Gram stain]], acid fast stain, fungal stain, and [[cultures]] of other body fluids ||❑ Therapeutic [[pericardiocentesis]] or [[pericardial window]]<br> ❑ [[Pericardiectomy]] may be used in treatment of recurrent [[pericardial efussion]] and in patients with dense adhesions, loculated and thick purulent effusion<br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antimicrobial therapy]] <br> :❑ Intiate antistaphylococcal antibiotic plus [[aminoglycoside]], followed by tailored antibiotic therapy according to pericardial fluid and blood cultures<br> :❑ Empiric regimen can be started for the following <br> ::❑ [[Immunosuppression]]<br> ::❑ Concurrent infection at another body site<br> ::❑ Presence of intravascular lines or prosthetic devices <br> ::❑ Recent antimicrobial therapy <br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antifungal therapy]] | ||
|- | |- | ||
| [[Tuberculous pericarditis]]|| ❑ Diagnostic [[pericardiocentesis]] in all suspected tuberculous pericarditis patients <br> :❑ [[PCR]] of pericardial fluid<br>:❑ High [[adenosine deaminase]] activity and interferon gamma concentration in [[pericardial effusion]] <br> ❑ Pericardial biopsy (rapid diagnosis) <br> ❑ [[Tuberculin skin test]] (not helpful) <br> ❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Culture of sputum, gastric aspirate, and/or urine <br>❑ Enzyme-linked immunospot (ELISPOT)<br> ❑ Serum titres of antimyolemmal and antimyosin antibodies||❑[[Tuberculous pericarditis medical therapy|Anti-tuberculosis chemotherapy]]<br> :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion<br> ❑ [[Pericardiectomy]] is warranted in the setting of persistent [[constrictive pericarditis]] or when no general improvement after 4-8 weeks following antituberculosis chemotherapy<br> ❑ [[Tuberculous pericarditis medical therapy#Role of Corticosteroids in Tuberculous pericarditis|Prednisone]] can be used. | | [[Tuberculous pericarditis]]|| ❑ Diagnostic [[pericardiocentesis]] in all suspected tuberculous pericarditis patients <br> :❑ [[PCR]] of pericardial fluid<br>:❑ High [[adenosine deaminase]] activity and interferon gamma concentration in [[pericardial effusion]] <br> ❑ Pericardial biopsy (rapid diagnosis) <br> ❑ [[Tuberculin skin test]] (not helpful) <br> ❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Culture of sputum, gastric aspirate, and/or urine <br>❑ Enzyme-linked immunospot (ELISPOT)<br> ❑ Serum titres of antimyolemmal and antimyosin antibodies||❑[[Tuberculous pericarditis medical therapy|Anti-tuberculosis chemotherapy]]<br> :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion<br> ❑ [[Pericardiectomy]] is warranted in the setting of persistent [[constrictive pericarditis]] or when no general improvement after 4-8 weeks following antituberculosis chemotherapy<br> ❑ [[Tuberculous pericarditis medical therapy#Role of Corticosteroids in Tuberculous pericarditis|Prednisone]] can be used. | ||
|- | |- | ||
| Neoplastic pericarditis ||❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Diagnostic [[pericardiocentesis]] ❑ Cytology and tumour markers <br> ❑ Pericardial biopsy || ❑ Systemic antineoplastic treatment <br> ❑ Assess the life expectancy of the patients before proceeding with the treatment<br> :❑ Better prognosis patients should be treated more aggressively <br> :❑ Advanced [[malignancy]] should be treated palliatively with [[pericardiocentesis]] <br> | | Neoplastic [[pericarditis]] ||❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Diagnostic [[pericardiocentesis]] when other tests couldnt identify [[malignancy]]<br>❑ Cytology and tumour markers <br> ❑ Pericardial biopsy || ❑ Systemic antineoplastic treatment <br> ❑ Assess the life expectancy of the patients before proceeding with the treatment<br> :❑ Better prognosis patients should be treated more aggressively <br> :❑ Advanced [[malignancy]] should be treated palliatively with [[pericardiocentesis]] <br> ❑ Recurrence of pericardial effusion is prevented using any of the following techniques <br> :❑ Prolonged pericardiocentesis <br> :❑ Pericardial sclerosis <br> :❑ Pericardiotomy <br> :❑ Intrapericardial chemotherapy | ||
|- | |- | ||
| Pericarditis in renal failure ||❑ Renal function test <br> ❑ Diagnostic [[pericardiocentesis]] <br> ❑ Pericardial biopsy || ❑ Uremic pericarditis <br> :❑ [[Hemodialysis]] or [[peritoneal dialysis]]<br> :❑ [[Heparin]]-free haemodialysis should be used <br> ❑ Dialysis-associated pericarditis <br> :❑ [[Pericardiocentesis]] for large effusion <br> :❑ Pericardiotomy in non resolving effusion<br> | | Pericarditis in [[renal failure]] ||❑ Renal function test <br> ❑ Diagnostic [[pericardiocentesis]] <br> ❑ Pericardial biopsy || ❑ Uremic pericarditis <br> :❑ [[Hemodialysis]] or [[peritoneal dialysis]]<br> :❑ [[Heparin]]-free haemodialysis should be used <br> ❑ Dialysis-associated pericarditis <br> :❑ [[Pericardiocentesis]] for large effusion <br> :❑ Pericardiotomy in non resolving effusion<br> | ||
|- | |- | ||
| Pericarditis in systemic autoimmune disease || ❑ Diagnostic [[pericardiocentesis]] <br> :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3<br> :❑ Antisarcolemmal antibodies<br> ❑ Exclusion of viral and bacterial etiologies|| ❑ [[NSAIDs]] or [[aspirin]] or [[colchicine]] <br> ❑ Systemic [[corticosteroid]] can be used <br> :❑ Intrapericardial steroids has less side effects and is highly effective | | Pericarditis in systemic [[autoimmune disease]] || ❑ Diagnostic [[pericardiocentesis]] <br> :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3<br> :❑ Antisarcolemmal antibodies<br> ❑ Exclusion of viral and bacterial etiologies|| ❑ [[NSAIDs]] or [[aspirin]] or [[colchicine]] <br> ❑ Systemic [[corticosteroid]] can be used <br> :❑ Intrapericardial steroids has less side effects and is highly effective | ||
|- | |- | ||
|} | |} | ||
==Do's== | ==Do's== | ||
*Always suspect [[acute pericarditis]] based on a history of characteristic pleuritic chest pain and on a [[pericardial friction rub]] finding. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly. | *Always suspect [[acute pericarditis]] based on a history of characteristic pleuritic chest pain and on a [[pericardial friction rub]] finding. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained [[cardiomegaly]]. | ||
* | * Focus on excluding a significant effusion or tamponade. Suspect acute [[cardiac tamponade]] in any patient presenting with [[Beck's triad]]: [[hypotension]], [[tachycardia]], muffled heart sounds and distended neck veins (or elevated [[jugular venous pressure]]).<ref name="Sternbach-">{{Cite journal | last1 = Sternbach | first1 = G. | last2 = Beck | first2 = C. | title = Claude Beck: cardiac compression triads. | journal = J Emerg Med | volume = 6 | issue = 5 | pages = 417-9 | month = | year = | doi = | PMID = 3066820 }}</ref> | ||
* [[NSAIDs]] are the mainstay in the treatment of uncomplicated [[acute pericarditis]] and [[ibuprofen]] is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range. | * [[NSAIDs]] are the mainstay in the treatment of uncomplicated [[acute pericarditis]] and [[ibuprofen]] is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range. | ||
* [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy. | * [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy. | ||
* | * Restrict systemic [[corticosteroid]] therapy to [[connective tissue diseases]], autoreactive or uremic pericarditis. Intrapericardial application avoids systemic side effects and is highly effective. | ||
* Use moderate initial dosing of steroids followed by a slow taper. | |||
* Introduce [[ibuprofen]] or [[colchicine]] early during tapering of steroids. | |||
* Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation. | * Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation. | ||
* Assess for the presence of [[coagulopathy]] or the intake of [[antithrombotic]] medications before choosing the modality of drainage of the pericardial fluid. | * Assess for the presence of [[coagulopathy]] or the intake of [[antithrombotic]] medications before choosing the modality of drainage of the pericardial fluid. |
Revision as of 00:08, 23 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]
Pericarditis Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Overview
Pericarditis refers to the inflammation of the fibroelastic sac surrounding the heart (pericardium), and it can be dry, fibrinous or effusive independently from the etiology. Myopericarditis, or perimyocarditis refers to acute pericarditis cases that also demonstrate myocardial inflammation resulting in global or regional myocardial dysfunction, elevations of troponins, creatine kinase MB, myoglobin and tumour necrosis factor.[1] Depending on the time of presentation and duration, pericarditis is divided into acute (<6 weeks), subacute (6 weeks to 6 months) and chronic (>6 months) forms. Acute pericarditis is more common than chronic pericarditis and always suspect acute pericarditis based on a history of characteristic pleuritic chest pain and on a pericardial friction rub finding. NSAIDs are the mainstay in the treatment of acute pericarditis and ibuprofen is the most preferred drug for its favourable effect on the coronary flow.[2]
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Autoimmune: Rheumatoid arthritis, Sjögren’s syndrome, SLE, systemic sclerosis, systemic vasculitis
- Bacterial: Coxiella burnetii, pneumococcus, staphylococcus, streptococcus, tuberculosis[3]
- Cardiovascular: Dressler's syndrome, postpericardiotomy syndrome, post-traumatic pericarditis[4]
- Idiopathic
- Metabolic: Myxedema, uremia
- Neoplastic: Breast cancer, leukemia, lung cancer, lymphoma
- Viral: Adeno virus, CMV, coxsackie, EBV, echovirus, HBV, HIV, human herpes virus 6, influenza, mumps, parvovirus B19, rubella, varicella[3]
Diagnosis
Shown below is an algorithm summarizing the diagnostic approach to acute pericarditis in adults.[2][5][4]
Characterize the symptoms: ❑ Chest pain:
Symptoms associated with pericardial effusion:
❑ With a hemodynamically significant pericardial effusion
Other etiology associated symptoms: Obtain a detailed history:
❑ Medications ❑ Systemic illness ❑ Others | |||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
Cardiovascular examination: Auscultation
Palpation:
Percussion:
Respiratory examination:
Abdominal examination:
| |||||||||||||||||||||||||||||||||||||||||||||||||
Order laboratory tests (urgent): ❑ CBC (leucocytosis) Order electrocardiogram (urgent): ❑ Typical findings in pericarditis
❑ Electrical alternans (in cardiac tamponade) Order imaging (urgent):
| |||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of acute pericarditis Atleast two of the following criteria:
❑ Suggestive EKG changes
❑ Suggestive echocardiography changes
| |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No or equivocal | ||||||||||||||||||||||||||||||||||||||||||||||||
Elevated cardiac enzymes or Global or regional myocardial dysfunction on echo | Suspicion of diagnosis of acute pericarditis ❑ Ongoing fever | ||||||||||||||||||||||||||||||||||||||||||||||||
No | Yes | Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||
Consider cardiac MRI (CMR))[7] | Consider alternative diagnosis and treat accordingly | ||||||||||||||||||||||||||||||||||||||||||||||||
Acute pericarditis | Myopericarditis | Treat as acute pericarditis or myopericarditis if there is delayed enhancement on CMR | |||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Treatment of Acute Pericarditis
Shown below is an algorithm summarizing the management of acute pericarditis in adults.[2][5][4]
Acute pericarditis or myopericarditis | |||||||||||||||||||||||||||||||||||||||||||
High risk features ❑ Fever >38°C | |||||||||||||||||||||||||||||||||||||||||||
Any one of the above high risk features | |||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||
Inpatient treatment | Outpatient treatment | ||||||||||||||||||||||||||||||||||||||||||
Stable | No pre-existing coronary artery disease | Pre-existing coronary artery disease | |||||||||||||||||||||||||||||||||||||||||
Initiate medical therapy NSAIDs
❑ Indomethacin:
❑ Stop anticoagulants if patient develops pericardial effusion
Order tests to identify the specific etiology ❑ Order specifc tests based on the clinical suspicion Order pericardiocentesis: ❑ When there is
| Click here for management of cardiac tamponade ❑ Immediately transfer the patient to ICU Initiate medical therapy NSAIDs
❑ Indomethacin:
❑ Stop anticoagulants if patient develops pericardial effusion
Order tests to identify the specific etiology ❑ Order specifc tests based on the clinical suspicion | Initiate medical therapy NSAID's
❑ Indomethacin:
❑ Add gastroprotective agents
Life style modification ❑ In case of pericarditis, avoid sternous physical activity until symptom resolution | Intitate aspirin therapy
❑ Add gastroprotective agents
❑ Stop anticoagulants if patient develops pericardial effusion Steroids Life style modification ❑ In case of pericarditis, avoid sternous physical activity until symptom resolution | ||||||||||||||||||||||||||||||||||||||||
Response to treatment | |||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||
Follow up ❑ Observe for recurrences or constriction | Hospital admission ❑ Indication that the underlying cause may not be viral or idiopathic in nature. | ||||||||||||||||||||||||||||||||||||||||||
Treatment of Recurrent Pericarditis
Shown below is an algorithm summarizing the management of recurrent pericarditis in adults which encompass the incessant type (relapses on discontinuation of anti-inflammatory) and the intermittent type (widely varying symptom free interval without medical therapy).[2][5][4]
Recurrent pericarditis | |||||||||||||||||||||||||||||||||||||||||||||||||
Characterize the clinical, EKG and imaging findings ❑ Characteristic acute pericarditis symptoms
| |||||||||||||||||||||||||||||||||||||||||||||||||
Initiate medical therapy NSAIDs
❑ Indomethacin:
❑ Stop anticoagulants if patient develops pericardial effusion
Life style modification ❑ Excercise restriction until symptom resolution | |||||||||||||||||||||||||||||||||||||||||||||||||
Multiple relapses | |||||||||||||||||||||||||||||||||||||||||||||||||
Positive response | No response | ||||||||||||||||||||||||||||||||||||||||||||||||
Taper steroids ❑ Taper dose over a three-month period
❑ Add colchicine or NSAIDs at the end of tapering of steroids | ❑ Add azathioprine (75–100 mg/day) or cyclophosphamide | ||||||||||||||||||||||||||||||||||||||||||||||||
Treatment failure | |||||||||||||||||||||||||||||||||||||||||||||||||
Pericardiectomy ❑ Maintain the patient on steroid free regimen for several weeks before the procedure ❑Order tests to identify the specific etiology and treat accordingly | |||||||||||||||||||||||||||||||||||||||||||||||||
Etiology Specific Management
Clinical subgroups | Specific investigations | Treatment |
---|---|---|
Viral pericarditis | ❑ Perform testing for viral etiologies in immunocompromised and HIV infected patients ❑ Diagnostic pericardiocentesis :❑ Analysis of pericardial fluid (transudate or exudate) :❑ PCR or in-situ hybridisation |
❑ CMV pericarditis: Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16 ❑ Coxsackie B pericarditis: Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week ❑ Adenovirus and parvovirus B19 perimyocarditis: Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours |
Purulent pericarditis | ❑ Diagnostic pericardiocentesis in cases of high clinical suspicion :❑ Gram stain, acid fast stain, fungal stain, and cultures of the pericardial fluid :❑ Protein, glucose and cell count ❑ Gram stain, acid fast stain, fungal stain, and cultures of other body fluids |
❑ Therapeutic pericardiocentesis or pericardial window ❑ Pericardiectomy may be used in treatment of recurrent pericardial efussion and in patients with dense adhesions, loculated and thick purulent effusion ❑ Antimicrobial therapy :❑ Intiate antistaphylococcal antibiotic plus aminoglycoside, followed by tailored antibiotic therapy according to pericardial fluid and blood cultures :❑ Empiric regimen can be started for the following ::❑ Immunosuppression ::❑ Concurrent infection at another body site ::❑ Presence of intravascular lines or prosthetic devices ::❑ Recent antimicrobial therapy ❑ Antifungal therapy |
Tuberculous pericarditis | ❑ Diagnostic pericardiocentesis in all suspected tuberculous pericarditis patients :❑ PCR of pericardial fluid :❑ High adenosine deaminase activity and interferon gamma concentration in pericardial effusion ❑ Pericardial biopsy (rapid diagnosis) ❑ Tuberculin skin test (not helpful) ❑ CT scan and/or MRI of the chest ❑ Culture of sputum, gastric aspirate, and/or urine ❑ Enzyme-linked immunospot (ELISPOT) ❑ Serum titres of antimyolemmal and antimyosin antibodies |
❑Anti-tuberculosis chemotherapy :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion ❑ Pericardiectomy is warranted in the setting of persistent constrictive pericarditis or when no general improvement after 4-8 weeks following antituberculosis chemotherapy ❑ Prednisone can be used. |
Neoplastic pericarditis | ❑ CT scan and/or MRI of the chest ❑ Diagnostic pericardiocentesis when other tests couldnt identify malignancy ❑ Cytology and tumour markers ❑ Pericardial biopsy |
❑ Systemic antineoplastic treatment ❑ Assess the life expectancy of the patients before proceeding with the treatment :❑ Better prognosis patients should be treated more aggressively :❑ Advanced malignancy should be treated palliatively with pericardiocentesis ❑ Recurrence of pericardial effusion is prevented using any of the following techniques :❑ Prolonged pericardiocentesis :❑ Pericardial sclerosis :❑ Pericardiotomy :❑ Intrapericardial chemotherapy |
Pericarditis in renal failure | ❑ Renal function test ❑ Diagnostic pericardiocentesis ❑ Pericardial biopsy |
❑ Uremic pericarditis :❑ Hemodialysis or peritoneal dialysis :❑ Heparin-free haemodialysis should be used ❑ Dialysis-associated pericarditis :❑ Pericardiocentesis for large effusion :❑ Pericardiotomy in non resolving effusion |
Pericarditis in systemic autoimmune disease | ❑ Diagnostic pericardiocentesis :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3 :❑ Antisarcolemmal antibodies ❑ Exclusion of viral and bacterial etiologies |
❑ NSAIDs or aspirin or colchicine ❑ Systemic corticosteroid can be used :❑ Intrapericardial steroids has less side effects and is highly effective |
Do's
- Always suspect acute pericarditis based on a history of characteristic pleuritic chest pain and on a pericardial friction rub finding. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly.
- Focus on excluding a significant effusion or tamponade. Suspect acute cardiac tamponade in any patient presenting with Beck's triad: hypotension, tachycardia, muffled heart sounds and distended neck veins (or elevated jugular venous pressure).[9]
- NSAIDs are the mainstay in the treatment of uncomplicated acute pericarditis and ibuprofen is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range.
- Heparin is recommended under strict observation for patients who need anticoagulant therapy.
- Restrict systemic corticosteroid therapy to connective tissue diseases, autoreactive or uremic pericarditis. Intrapericardial application avoids systemic side effects and is highly effective.
- Use moderate initial dosing of steroids followed by a slow taper.
- Introduce ibuprofen or colchicine early during tapering of steroids.
- Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation.
- Assess for the presence of coagulopathy or the intake of antithrombotic medications before choosing the modality of drainage of the pericardial fluid.
- Choose pericardiocentesis rather than surgical drainage as a therapeutic option unless the patient has an indication for surgical drainage.
- Consider surgical drainage in aortic dissection and myocardial rupture.[10]
- When surgical drainage is indicated but the patient has severe hypotension prohibiting the induction of anesthesia, perform pericardiocentesis in the operating room before surgery.[10]
- Monitor closely patients who underwent pericardiocentesis for postdrainage decompensation.
Dont's
- Never delay treatment whenever cardiac tamponade is suspected.
- Avoid pericardiocentesis in cases where the diagnosis can be made based on other systemic features or when the effusions are very small or resolving under antiinflammatory treatment
- Don't perform pericardiocentesis in aortic dissection and ruptured ventricular aneurysm and avoid in cases of uncorrected coagulopathy, anticoagulant therapy, thrombocytopenia < 50,000/mm 3 , small, posterior, and loculated effusions.
References
- ↑ Imazio M (2012). "Contemporary management of pericardial diseases". Curr Opin Cardiol. 27 (3): 308–17. doi:10.1097/HCO.0b013e3283524fbe. PMID 22450720.
- ↑ 2.0 2.1 2.2 2.3 Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y; et al. (2004). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". Eur Heart J. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. PMID 15120056.
- ↑ 3.0 3.1 Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010). "Controversial issues in the management of pericardial diseases". Circulation. 121 (7): 916–28. doi:10.1161/CIRCULATIONAHA.108.844753. PMID 20177006.
- ↑ 4.0 4.1 4.2 4.3 Lange RA, Hillis LD (2004). "Clinical practice. Acute pericarditis". N Engl J Med. 351 (21): 2195–202. doi:10.1056/NEJMcp041997. PMID 15548780.
- ↑ 5.0 5.1 5.2 Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B; et al. (2013). "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography". J Am Soc Echocardiogr. 26 (9): 965–1012.e15. doi:10.1016/j.echo.2013.06.023. PMID 23998693.
- ↑ "WHO launches World health report 2013". Euro Surveill. 18 (33): 20559. 2013. PMID 23968879.
- ↑ Khandaker MH, Espinosa RE, Nishimura RA; et al. (2010). "Pericardial disease: diagnosis and management". Mayo Clinic Proceedings. Mayo Clinic. 85 (6): 572–93. doi:10.4065/mcp.2010.0046. PMC 2878263. PMID 20511488. Unknown parameter
|month=
ignored (help) - ↑ 8.0 8.1 8.2 8.3 Goldfinger S (2014). "A randomized trial of colchicine for acute pericarditis". N Engl J Med. 370 (8): 780. doi:10.1056/NEJMc1315351#SA1. PMID 24552334.
- ↑ Sternbach, G.; Beck, C. "Claude Beck: cardiac compression triads". J Emerg Med. 6 (5): 417–9. PMID 3066820.
- ↑ 10.0 10.1 Schiavone WA (2013). "Cardiac tamponade: 12 pearls in diagnosis and management". Cleve Clin J Med. 80 (2): 109–16. doi:10.3949/ccjm.80a.12052. PMID 23376916.